Lab Automation Market to Reach USD 16.1 Billion by 2035, Growing at 9.5% CAGR | Abbott, Beckman Coulter, Roche Diagnostics

The global lab automation market, valued at USD 6.5 billion in 2025, is on track to reach USD 7.1 billion in 2026 and USD 16.1 billion by 2035, expanding at a compound annual growth rate of 9.5% over the forecast period 2026 to 2035, according to a new market intelligence report published by Roots Analysis. The market's expansion is driven by surging demand for biopharmaceutical development, a pressing need to eliminate human error in diagnostics, and the rapid integration of AI and robotic technologies into laboratory workflows.

To explore the complete findings, request a free sample of the report at https://www.rootsanalysis.com/reports/lab-automation-market/request-sample.html

Market Overview
Lab automation covers the integration of instruments, software, and robotic systems into laboratory environments to execute tasks with minimal hands-on involvement from scientists. The technology applies across a broad spectrum of operations and sample preparation to nucleic acid extraction, microplate reading, data analysis, and inventory management. Its core value proposition is straightforward: automation reduces operator-to-operator variability, cuts labor costs, and delivers results with a level of reproducibility that manual methods cannot reliably achieve.

The case for widespread adoption grows stronger year after year. A study published in Nature found that over 70% of scientists were unable to replicate a previously published experiment, a statistic that has placed reproducibility at the center of laboratory quality management conversations worldwide. Automated sampling systems directly address this problem, reducing deviations by approximately 65% and lifting overall lab productivity by up to 80%. These measurable gains are making the business case for automation compelling for everything from small academic labs to large-scale clinical and pharmaceutical facilities.

Real-world investment continues to accelerate this trajectory. In February 2026, Automata secured USD 45 million in a Series C funding round to build AI-ready lab infrastructure and deepen its partnership with Danaher. In February 2024, Monomer Bio raised USD 5.6 million in seed funding specifically to develop an AI-powered lab automation platform aimed at accelerating drug discovery. Abbott's March 2024 launch of its GLP Systems Track in India and Kokilaben Dhirubhai Ambani Hospital's deployment of total lab automation in partnership with Roche Diagnostics in June 2023 illustrate how adoption is broadening across geographies and healthcare settings.

Key Growth Drivers
Rising Demand for Biopharmaceutical Development: The global push to develop complex biologics, cell and gene therapies, and personalized medicines has dramatically increased the volume and complexity of laboratory work. Pharmaceutical and biotechnology companies are investing in automated platforms to handle higher throughput without proportionally increasing headcount or error rates. With drug pipelines growing in complexity, manual processes simply cannot scale at the pace that R&D timelines require.

Error Reduction and Reproducibility Imperative: Regulatory agencies and quality management standards are placing greater emphasis on data traceability and process consistency. Lab automation directly reduces human error in the pre-analytical stage of diagnostics, where the majority of errors occur. Systems capable of real-time data monitoring and standardized workflows are no longer optional for labs seeking accreditation or regulatory approval.

AI and Robotics Integration: Manufacturers are embedding AI-enhanced features into liquid handling and imaging platforms at a rapid pace. Beckman Coulter Life Sciences launched its Biomek i-Series automated liquid handler with modular AI enhancements in November 2025, specifically targeting drug discovery pipelines. This convergence of robotics and machine intelligence is enabling labs to run more experiments with less manual intervention, shortening timelines and improving data quality simultaneously.

Growing Patent Activity and Venture Investment: Over 6,200 patents focused on lab automation have been filed or granted in the past six years, signaling that innovation in this space is intensifying. Concurrent venture investment, including Trilobio's USD 8 million raise in May 2025 to commercialize a robotic lab-in-a-box for biologists, confirms that startups see significant commercial opportunity and are actively challenging established players.

Strategic Partnerships and Platform Expansion: Collaboration between robotics companies and analytical instrument manufacturers is accelerating product development. ABB Robotics entered into a collaboration with Agilent Technologies in January 2025 to develop integrated automated laboratory solutions. Similarly, Beckman Coulter Life Sciences partnered with Automata in January 2026 to connect liquid handling and genomic technologies to Automata's LINQ automation platform. These alliances are creating integrated, end-to-end automation ecosystems that raise switching costs and expand addressable markets.

Market Segmentation
The lab automation market breaks down by stage of automation (pre-analytical, analytical, post-analytical, and total lab automation), type of instrument, application, end user, and geography. Among stages, the pre-analytical segment commands the most attention because it carries the highest error risk in laboratory diagnostics. Correcting errors at this stage prevents downstream failures that are far more costly to remediate. By instrument type, automated liquid handling systems hold the largest share of the market. Liquid handling technology has expanded well beyond pharmaceutical labs into academic research settings, and manufacturers continue to add features targeting precision at nanoliter volumes. Hamilton's Microlab STAR Liquid Handling System, recognized with a 2022 Good Design Award, illustrates how the category is evolving in both function and form. Among applications, diagnostics and genomic solutions represent the largest and most active areas of demand. By end user, pharmaceutical and biotechnology companies account for the dominant share, given their large-scale testing requirements, but research and diagnostic laboratories are closing the gap as automation becomes more accessible and modular.

Approximately 50% of the roughly 350 companies currently manufacturing lab automation systems are focused specifically on automated liquid handling, underlining where commercial competition is most intense. Growth in the automated storage and retrieval systems (ASRS) segment is also notable, as these systems reduce variable costs by eliminating manual inventory tasks while improving accountability and security in high-value sample environments.

To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/lab-automation-market/request-quote.html

Regional Insights
North America currently holds the leading position in the global lab automation market, supported by a mature biopharmaceutical industry, high healthcare spending, a dense concentration of research institutions, and a regulatory environment that favors automation-driven quality assurance. The United States in particular has a long history of adopting lab automation at scale in clinical and pharmaceutical settings, giving North American companies both first-mover advantages and deep customer relationships.

Europe represents the second-largest regional market, anchored by strong pharmaceutical manufacturing clusters in Germany, Switzerland, and the United Kingdom, alongside well-funded academic research programs. Regulatory requirements under the European Medicines Agency for data integrity and process validation continue to push laboratories toward automated solutions.
Asia-Pacific is the fastest-growing region, and the structural factors behind that growth are durable. Significant healthcare infrastructure investment by governments across India, China, Japan, and South Korea, combined with a rapidly growing pharmaceutical manufacturing base and rising diagnostic volumes, is generating sustained demand for lab automation systems. Abbott's launch of the GLP Systems Track in India in early 2024 and the high-profile adoption of total lab automation at Kokilaben Dhirubhai Ambani Hospital signal that the market is moving beyond early adoption into mainstream deployment across the region.

Competitive Landscape
Key players operating in the lab automation market include Abbott, Anton Paar, BD, Beckman Coulter, ERWEKA, Leuze, Ortho Clinical Diagnostics, Pall Corporation, PerkinElmer, Roche Diagnostics, Siemens Healthineers, and SYSTAG. The broader ecosystem encompasses approximately 350 companies with the technical capabilities to manufacture lab automation systems.

The market shows characteristics of both consolidation and disruption. Established players are extending their platforms through strategic acquisitions, distribution agreements, and technology licensing, while well-funded startups are targeting specific workflow pain points, particularly in drug discovery and genomics. The primary competitive battlegrounds are AI integration, platform modularity, and the ability to offer end-to-end workflow solutions rather than standalone instruments. Companies that build open, interoperable platforms with strong software layers are gaining advantage as customers increasingly prioritize total workflow efficiency over individual instrument performance.

Browse Full Report Description + Research Methodology + Table of Content + Infographics here:
https://www.rootsanalysis.com/reports/lab-automation-market.html

Contact Details
Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com
Website: https://www.rootsanalysis.com

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.